The glucose trap: why "normal" fasting glucose is misleading

Fasting glucose is the most commonly tested metabolic marker. If it's below 100 mg/dL, your doctor says it's normal. Between 100-125 mg/dL is prediabetes. Above 126 mg/dL is diabetes. Simple, binary, and dangerously incomplete[1].

The problem: fasting glucose is the last metabolic marker to become abnormal. By the time your fasting glucose rises above 100 mg/dL, you've likely had insulin resistance for 5-15 years. That's because the body has an extraordinary compensation mechanism — when cells become resistant to insulin, the pancreas simply produces more insulin to force glucose into cells. This hyperinsulinemia keeps fasting glucose in the "normal" range for years, sometimes decades, while metabolic damage accumulates silently[2].

Key distinction
Fasting glucose tells you the score of the game. Fasting insulin tells you how hard the pancreas is working to keep that score. A "normal" glucose of 95 mg/dL with a fasting insulin of 20 mIU/L is not the same as a glucose of 85 mg/dL with an insulin of 5 mIU/L. The first is a pancreas in distress; the second is metabolic health.

What HbA1c actually measures

Glycated hemoglobin (HbA1c) measures the percentage of hemoglobin molecules that have glucose permanently attached to them. Because red blood cells live for approximately 120 days, HbA1c reflects your average blood glucose over the past 2-3 months[1].

This makes HbA1c far more stable and reliable than a single fasting glucose measurement, which can fluctuate based on what you ate the night before, how well you slept, your stress level, or whether you had coffee. HbA1c doesn't care about any of that — it's an average.

HbA1c levelClassificationAverage glucose (approx.)
< 5.0%Optimal~97 mg/dL
5.0-5.4%Normal97-108 mg/dL
5.5-5.6%Borderline — monitor111-117 mg/dL
5.7-6.4%Prediabetes117-137 mg/dL
≥ 6.5%Diabetes≥ 140 mg/dL

What the table doesn't show: even within the "normal" range, HbA1c is a continuous risk marker. A large meta-analysis published in the BMJ found that the risk of cardiovascular disease and all-cause mortality begins to increase at HbA1c levels above approximately 5.0%, with a clear dose-response relationship — the higher the HbA1c, the higher the risk, even below the diabetes threshold[3].

Fasting insulin: the early warning marker your doctor doesn't test

Fasting insulin is arguably the single most important metabolic marker that isn't part of standard screening. It measures how much insulin your pancreas is producing in the fasting state to maintain a given blood glucose level. If fasting glucose is the "what," fasting insulin is the "how hard"[2].

The insulin resistance timeline

Metabolic dysfunction doesn't happen overnight. It follows a predictable, years-long timeline:

  1. Phase 1 — Early insulin resistance (5-15 years before diagnosis): Cells begin resisting insulin. The pancreas compensates by producing more. Fasting glucose is normal. Fasting insulin is elevated. HbA1c is normal or borderline. This is the window where intervention is most effective.
  2. Phase 2 — Impaired glucose tolerance (2-10 years before diagnosis): The pancreas is struggling to keep up. Post-meal glucose spikes become higher and last longer. Fasting glucose may still be normal, but HbA1c starts creeping up (5.5-6.0%). HOMA-IR is elevated.
  3. Phase 3 — Prediabetes (1-5 years before diagnosis): Fasting glucose rises above 100 mg/dL. HbA1c reaches 5.7-6.4%. Beta-cell function is declining. The pancreas is losing the compensation battle.
  4. Phase 4 — Type 2 diabetes: Fasting glucose above 126 mg/dL. HbA1c above 6.5%. Beta-cell function has declined significantly. This is where most people are diagnosed — a decade or more after the problem started.
By the time fasting glucose is abnormal, the pancreas has been compensating for years. Fasting insulin catches the problem in Phase 1 — the window where lifestyle intervention can prevent diabetes entirely.

HOMA-IR: calculating insulin resistance

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a simple, validated calculation that combines fasting insulin and fasting glucose to estimate insulin resistance[4]:

HOMA-IR = (Fasting Insulin [mIU/L] x Fasting Glucose [mg/dL]) / 405

HOMA-IR scoreInterpretation
< 1.0Optimal insulin sensitivity
1.0-1.5Healthy
1.5-2.0Early insulin resistance — monitor
2.0-2.5Moderate insulin resistance
> 2.5Significant insulin resistance — intervention recommended

Example: Fasting glucose of 95 mg/dL, fasting insulin of 15 mIU/L. HOMA-IR = (15 x 95) / 405 = 3.5. This person's fasting glucose is "normal" but their HOMA-IR indicates significant insulin resistance. Without fasting insulin, this would be invisible.

The metabolic syndrome connection

Insulin resistance is the root cause of metabolic syndrome — a cluster of conditions that dramatically increases cardiovascular disease risk. Metabolic syndrome is defined as having three or more of[5]:

The underlying driver of all five criteria is insulin resistance. Elevated insulin promotes sodium retention (raising blood pressure), increases hepatic VLDL production (raising triglycerides and lowering HDL), promotes visceral fat storage (increasing waist circumference), and eventually raises glucose when compensation fails. Addressing insulin resistance addresses the root cause, not just the individual symptoms[2].

Lipa analyzes this marker
See your metabolic health beyond just glucose
Lipa reads your HbA1c, fasting glucose, and fasting insulin together — calculating HOMA-IR and identifying early insulin resistance that standard glucose-only testing misses. We show you where you are on the metabolic spectrum and what the research says about your specific numbers.
Get started free

Reversing insulin resistance: what the evidence says

The most important finding in metabolic health research over the past 25 years is that insulin resistance is reversible — particularly in the early stages. The Diabetes Prevention Program (DPP), one of the most significant clinical trials in preventive medicine, demonstrated that intensive lifestyle intervention reduced the progression from prediabetes to type 2 diabetes by 58% — more effective than metformin (31% reduction)[6].

Exercise: the single most potent insulin sensitizer

Exercise improves insulin sensitivity through multiple mechanisms — it increases glucose transporter (GLUT4) translocation to the cell surface (allowing glucose to enter muscle cells without insulin), reduces visceral fat, improves mitochondrial function, and enhances post-receptor insulin signaling[7].

Dietary changes

Sleep: the overlooked metabolic lever

Sleep restriction directly impairs insulin sensitivity. A study in Annals of Internal Medicine found that restricting sleep to 4.5 hours per night for just four nights reduced insulin sensitivity by 16% and reduced the insulin response to glucose by 30%[12]. Conversely, improving sleep duration from 6 to 7-8 hours is associated with measurable improvements in fasting insulin and HOMA-IR. Sleep quality matters too — fragmented sleep and sleep apnea both worsen insulin resistance independent of sleep duration.

Body composition: visceral fat is the target

Visceral fat (fat stored around internal organs, particularly in the abdomen) is metabolically active and insulin-resistant. It secretes pro-inflammatory cytokines (IL-6, TNF-alpha) and free fatty acids that directly impair insulin signaling in the liver and muscle. Even modest weight loss — 5-10% of body weight — can dramatically improve insulin sensitivity if it reduces visceral fat. Waist circumference is a better predictor of insulin resistance than BMI.

Bottom line
HbA1c and fasting insulin together reveal metabolic dysfunction years before fasting glucose becomes abnormal. If your fasting insulin is above 8-10 mIU/L, your HOMA-IR is above 1.5, or your HbA1c is above 5.4%, you have an early warning — and a window to reverse the trajectory. Exercise (both aerobic and resistance), dietary carbohydrate reduction, adequate sleep (7-8 hours), and visceral fat loss are the most evidence-backed interventions. The Diabetes Prevention Program proved that lifestyle intervention outperforms medication for preventing progression to diabetes.